Filtered By:
Condition: Atrial Fibrillation
Countries: Turkey Health
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 89 results found since Jan 2013.
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Scanning of paroxysmal atrial fibrillation as an etiological risk factor in patients with acute ischemic stroke: prospective study
CONCLUSIONS: Detecting the presence of PAF by screening patients with no AF in the ECG through Holter ECG examinations is valuable in terms of changing the course of the treatment. It should be kept in mind that the possibility of accompanying PAF cannot be ruled out in the presence of other factors that pose a risk of stroke.PMID:35195235 | DOI:10.1590/1516-3180.2021.0156.R2.08062021
Source: Sao Paulo Medical Journal - February 23, 2022 Category: General Medicine Authors: Zahide Bet ül Gündüz Ahmet Lutfi Sertdemir Zafer Buyukterzi Source Type: research
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry
CONCLUSION: This registry obtained an important overview of the current safety and effectiveness of the dabigatran etexilate in Turkey. Our results indicate similar rates of thromboembolic and bleeding events with pivotal phase 3 trial and other real-life registries. However, rate of undertreatment usage of dabigatran etexilate in real life was found to be considerable.PMID:34881702 | DOI:10.5543/tkda.2021.07734
Source: Turk Kardiyoloji Dernegi arsivi - December 9, 2021 Category: Cardiology Authors: Cihan Alt ın Caner Topalo ğlu Nurullah Çetin Onur Dalg ıç Veysel Yavuz Emin Alio ğlu Nazile Bilgin Cenk Ekmek çi Nihat Pekel Mehmet Emre Özpelit E şref Tunçer Ebru İpek Türkoğlu Kamil T ülüce Umut Kocaba ş K ıvanç Yüksel U ğur Önsel T Source Type: research
